FDA Says Goodbye to Emergency Plasma Therapy for COVID Patients
Published Date: 10/2/2025
Notice
Summary
The FDA is ending the special emergency approval for using COVID-19 convalescent plasma as a treatment. This change affects healthcare providers and patients who used this plasma during the pandemic. The revocation means this treatment won’t be authorized anymore, but it won’t cost anyone extra or happen suddenly—it’s a clear update based on new information.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
EUA Revoked for COVID-19 Plasma
The FDA revoked the Emergency Use Authorization (EUA) for COVID-19 convalescent plasma. This means the plasma treatment is no longer authorized for use and the change affects healthcare providers and patients who used this plasma during the pandemic. The FDA stated the revocation will not impose extra costs on people and will not occur suddenly.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-19267 — Notice of Request for Revision of a Currently Approved Information Collection; Comments Requested
The Rural Utilities Service wants to update a form they use and needs your thoughts before asking for official approval. This affects folks who work with rural utilities and could change how they share info, but no big costs or deadlines yet. It’s your chance to speak up and help shape the process!
Next: 2025-19271 — 60-Day Notice of Proposed Information Collection: Standards for Success Reporting
HUD wants to update how they collect info about success stories from programs they fund. This affects organizations that report to HUD, asking them to share clearer, easier-to-understand results. They’re asking for public feedback over the next 60 days before making changes, aiming to keep things simple without adding extra costs or paperwork.